BPaQ

BPaQ is an investigational combination anti-tuberculosis regimen consisting of bedaquiline, pretomanid, and quabodepistat (OPC-167832). Developed by Otsuka Pharmaceutical, the regimen is designed to treat rifampicin-resistant (RR-TB) and multidrug-resistant tuberculosis (MDR-TB). Quabodepistat is a novel carbostyril derivative that acts as a potent inhibitor of decaprenylphosphoryl-β-D-ribose-2'-oxidase (DprE1), an essential enzyme for Mycobacterium tuberculosis to synthesize the cell wall component arabinogalactan. Bedaquiline inhibits mycobacterial ATP synthase, disrupting energy production, while pretomanid is a nitroimidazole that inhibits mycolic acid synthesis and causes respiratory poisoning in the bacteria. The regimen is currently being evaluated in the Phase 3 QUANTUM-TB trial to determine if it can shorten treatment duration to 4 or 6 months compared to the current standard of care.

Other names

Bedaquiline + Pretomanid + Quabodepistat